Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Bright Minds Biosciences ...

    NASDAQ: DRUG · Real-Time Price · USD
    28.04
    0.46 (1.67%)
    At close: Jun 16, 2025, 3:59 PM
    27.30
    -2.64%
    After-hours: Jun 16, 2025, 06:07 PM EDT

    Bright Minds Biosciences Statistics

    Share Statistics

    Bright Minds Biosciences has - shares outstanding. The number of shares has increased by 57.8% in one year.

    Shares Outstanding

    n/a
    		 n/a

    Shares Change (YoY)

    n/a
    		 57.8%

    Shares Change (QoQ)

    n/a
    		 1.37%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 4.93M

    Failed to Deliver (FTD) Shares

    n/a
    		 702

    FTD / Avg. Volume

    n/a
    		 2.38%

    Short Selling Information

    The latest short interest is 79.62K, so 1.13% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 79.62K

    Short % of Shares Out

    n/a
    		 1.13%

    Short % of Float

    n/a
    		 1.66%

    Short Ratio (days to cover)

    n/a
    		 2.63

    Valuation Ratios

    The PE ratio is -2.43 and the forward PE ratio is -7.17. Bright Minds Biosciences's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -2.43

    Forward PE

    n/a
    		 -7.17

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 4.6

    PB Ratio

    n/a
    		 1.23

    P/FCF Ratio

    n/a
    		 -3.69

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Bright Minds Biosciences.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 11.32, with a Debt / Equity ratio of 0.02.

    Current Ratio

    n/a
    		 11.32

    Quick Ratio

    n/a
    		 11.32

    Debt / Equity

    n/a
    		 0.02

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 -0.06

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 n/a

    Employee Count

    n/a
    		 undefined

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 2622.33% in the last 52 weeks. The beta is 0.45, so Bright Minds Biosciences's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.45

    52-Week Price Change

    n/a
    		 2622.33%

    50-Day Moving Average

    n/a
    		 30.32

    200-Day Moving Average

    n/a
    		 30.48

    Relative Strength Index (RSI)

    n/a
    		 45.6

    Average Volume (20 Days)

    n/a
    		 29,434

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -2.62M

    Net Income

    n/a
    		 -2.8M

    EBITDA

    n/a
    		 n/a

    EBIT

    n/a
    		 -2.62M

    Earnings Per Share (EPS)

    n/a
    		 -0.65
    Full Income Statement

    Balance Sheet

    The company has 5.72M in cash and 118.96K in debt, giving a net cash position of 5.6M.

    Cash & Cash Equivalents

    n/a
    		 5.72M

    Total Debt

    n/a
    		 118.96K

    Net Cash

    n/a
    		 5.6M

    Retained Earnings

    n/a
    		 -34.35M

    Total Assets

    n/a
    		 58.4M

    Working Capital

    n/a
    		 57.76M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -1.85M and capital expenditures 0, giving a free cash flow of -1.85M.

    Operating Cash Flow

    n/a
    		 -1.85M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -1.85M

    FCF Per Share

    n/a
    		 -0.43
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    DRUG does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for DRUG is $82.5, which is 194.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $82.5

    Price Target Difference

    n/a
    		 194.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jul 14, 2023. It was a backward split with a ratio of 1:5.

    Last Split Date

    n/a
    		 Jul 14, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:5

    Scores

    Altman Z-Score

    n/a
    		 203.56

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist